STP355 / Sirnaomics - LARVOL DELTA

Identification of siRNA silencing TGFβ1 and VEGFR2 and utility of the combination in targeting immune modulation and angiogenesis in treating melanoma in vivo. (PubMed, NAR Cancer) - "STP355 also reduced tumor weight significantly, without the toxicity observed with cisplatin, resulting in prolonged survival of mice compared with this small molecule. It increased immune cell penetration into TME and reduced metastases to the lung. STP355 was more efficacious than, and somewhat additive with, immune checkpoint inhibitory monoclonal antibodies."

IO biomarker • Journal • Preclinical • Immune Modulation • Immunology • Melanoma • Oncology • Solid Tumor • KDR • TGFB1

Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit (PRNewswire) - "Sirnaomics Ltd...announced today that the Company's Executive Director and Chief Medical Officer, Dr. Michael Molyneaux, will present clinical study results of its leading product candidate STP705 for the treatment of non-melanoma skin cancers, and the Company's clinical development strategy based on its strong presence in both the U.S. and China, at the 2022 Pre-ASCO (American Society of Clinical Oncology) China Summit...on May 21, 2022 with a live Zoom Webinar....the Company intends to file INDs to initiate clinical studies in 2023 for three programs currently in later preclinical stage: STP355 for colorectal cancer and melanoma, STP369 for head and neck cancer and bladder cancer, and STP779 for cholangiocarcinoma."

Clinical data • IND • Biliary Cancer • Biliary Tract Cancer • Bladder Cancer • Cholangiocarcinoma • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Melanoma • Non-melanoma Skin Cancer • Oncology • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Urothelial Cancer